Cargando…

Time to Start Delivering Iron Chelation Therapy in Newly Diagnosed Severe β-Thalassemia

BACKGROUND: Iron overload is still a major complication of severe β-thalassemia. Indication to start iron chelation therapy is based on serum ferritin (SF) or transferrin saturation (TS) level or the amount of transfusion. The goal of this study is to analyse the pattern of iron status, the amount o...

Descripción completa

Detalles Bibliográficos
Autores principales: Susanah, Susi, Idjradinata, Ponpon S., Sari, Nur M., Rakhmilla, Lulu E., Sribudiani, Yunia, Trisaputra, Jessica O., Moestopo, Octawyana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7752293/
https://www.ncbi.nlm.nih.gov/pubmed/33415156
http://dx.doi.org/10.1155/2020/8185016
_version_ 1783625830435389440
author Susanah, Susi
Idjradinata, Ponpon S.
Sari, Nur M.
Rakhmilla, Lulu E.
Sribudiani, Yunia
Trisaputra, Jessica O.
Moestopo, Octawyana
author_facet Susanah, Susi
Idjradinata, Ponpon S.
Sari, Nur M.
Rakhmilla, Lulu E.
Sribudiani, Yunia
Trisaputra, Jessica O.
Moestopo, Octawyana
author_sort Susanah, Susi
collection PubMed
description BACKGROUND: Iron overload is still a major complication of severe β-thalassemia. Indication to start iron chelation therapy is based on serum ferritin (SF) or transferrin saturation (TS) level or the amount of transfusion. The goal of this study is to analyse the pattern of iron status, the amount of transfusion regarding the time to start iron chelator, and serum hepcidin levels in newly diagnosed severe β-thalassemia. METHODS: A prospective cohort study was performed at Hasan Sadikin General Hospital on newly diagnosed severe β-thalassemia patients. Subjects had not received any blood transfusion with normal liver function test, CRP, and IL-6 levels who consumed normal diet according to age. The SF and TS levels indicate iron status, while hepcidin level indicates iron regulator status. Main indicator to start iron chelation therapy when SF level ≥1.000 ng/mL, TS level ≥70%, or after receiving transfusion at least 10 times. Statistical analysis used Mann–Whitney and Spearman. RESULTS: Forty-two newly severe β-thalassemia, 30 (71.4%), were diagnosed before 1 year old, mean 9.9 ± 6.4 months, range 2–24 months. Range amount of transfusion until SF level reached ≥1,000 ng/mL were 4-12 times, mean 7 ± 2 times. Mean SF and TS level at diagnosis were 365.6 ± 194.9 ng/mL and 67.3 ± 22.5%, while hepcidin level was normal, mean 242.6 ± 58 ng/mL. 36/42 patients have reached SF >1000 ng/mL with amount of transfusion less than 10 times. There was no significant difference of SF, TS, and hepcidin levels when SF >1000 ng/mL in the group with amount of transfusion 7–12 and less than 7 (p = 0.454, p = 0.084, p = 0.765), respectively. A significant positive correlation between SF and amount of transfusion was observed (p < 0.001; r = 0.781). CONCLUSION: Iron overload in severe β-thalassemia patients might occur earlier even before they received 10 times transfusion. Hepcidin serum level tends to increase when iron overload just started.
format Online
Article
Text
id pubmed-7752293
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-77522932021-01-06 Time to Start Delivering Iron Chelation Therapy in Newly Diagnosed Severe β-Thalassemia Susanah, Susi Idjradinata, Ponpon S. Sari, Nur M. Rakhmilla, Lulu E. Sribudiani, Yunia Trisaputra, Jessica O. Moestopo, Octawyana Biomed Res Int Research Article BACKGROUND: Iron overload is still a major complication of severe β-thalassemia. Indication to start iron chelation therapy is based on serum ferritin (SF) or transferrin saturation (TS) level or the amount of transfusion. The goal of this study is to analyse the pattern of iron status, the amount of transfusion regarding the time to start iron chelator, and serum hepcidin levels in newly diagnosed severe β-thalassemia. METHODS: A prospective cohort study was performed at Hasan Sadikin General Hospital on newly diagnosed severe β-thalassemia patients. Subjects had not received any blood transfusion with normal liver function test, CRP, and IL-6 levels who consumed normal diet according to age. The SF and TS levels indicate iron status, while hepcidin level indicates iron regulator status. Main indicator to start iron chelation therapy when SF level ≥1.000 ng/mL, TS level ≥70%, or after receiving transfusion at least 10 times. Statistical analysis used Mann–Whitney and Spearman. RESULTS: Forty-two newly severe β-thalassemia, 30 (71.4%), were diagnosed before 1 year old, mean 9.9 ± 6.4 months, range 2–24 months. Range amount of transfusion until SF level reached ≥1,000 ng/mL were 4-12 times, mean 7 ± 2 times. Mean SF and TS level at diagnosis were 365.6 ± 194.9 ng/mL and 67.3 ± 22.5%, while hepcidin level was normal, mean 242.6 ± 58 ng/mL. 36/42 patients have reached SF >1000 ng/mL with amount of transfusion less than 10 times. There was no significant difference of SF, TS, and hepcidin levels when SF >1000 ng/mL in the group with amount of transfusion 7–12 and less than 7 (p = 0.454, p = 0.084, p = 0.765), respectively. A significant positive correlation between SF and amount of transfusion was observed (p < 0.001; r = 0.781). CONCLUSION: Iron overload in severe β-thalassemia patients might occur earlier even before they received 10 times transfusion. Hepcidin serum level tends to increase when iron overload just started. Hindawi 2020-12-13 /pmc/articles/PMC7752293/ /pubmed/33415156 http://dx.doi.org/10.1155/2020/8185016 Text en Copyright © 2020 Susi Susanah et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Susanah, Susi
Idjradinata, Ponpon S.
Sari, Nur M.
Rakhmilla, Lulu E.
Sribudiani, Yunia
Trisaputra, Jessica O.
Moestopo, Octawyana
Time to Start Delivering Iron Chelation Therapy in Newly Diagnosed Severe β-Thalassemia
title Time to Start Delivering Iron Chelation Therapy in Newly Diagnosed Severe β-Thalassemia
title_full Time to Start Delivering Iron Chelation Therapy in Newly Diagnosed Severe β-Thalassemia
title_fullStr Time to Start Delivering Iron Chelation Therapy in Newly Diagnosed Severe β-Thalassemia
title_full_unstemmed Time to Start Delivering Iron Chelation Therapy in Newly Diagnosed Severe β-Thalassemia
title_short Time to Start Delivering Iron Chelation Therapy in Newly Diagnosed Severe β-Thalassemia
title_sort time to start delivering iron chelation therapy in newly diagnosed severe β-thalassemia
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7752293/
https://www.ncbi.nlm.nih.gov/pubmed/33415156
http://dx.doi.org/10.1155/2020/8185016
work_keys_str_mv AT susanahsusi timetostartdeliveringironchelationtherapyinnewlydiagnosedseverebthalassemia
AT idjradinataponpons timetostartdeliveringironchelationtherapyinnewlydiagnosedseverebthalassemia
AT sarinurm timetostartdeliveringironchelationtherapyinnewlydiagnosedseverebthalassemia
AT rakhmillalulue timetostartdeliveringironchelationtherapyinnewlydiagnosedseverebthalassemia
AT sribudianiyunia timetostartdeliveringironchelationtherapyinnewlydiagnosedseverebthalassemia
AT trisaputrajessicao timetostartdeliveringironchelationtherapyinnewlydiagnosedseverebthalassemia
AT moestopooctawyana timetostartdeliveringironchelationtherapyinnewlydiagnosedseverebthalassemia